Inflammation and the Heart
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Studies have shown that people with rheumatoid arthritis (RA) have a higher rate of heart disease than people that do not have RA. we believe this is caused by the inflammation produced by RA.
| Condition |
|---|
|
Rheumatoid Arthritis |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Prospective |
| Official Title: | Inflammation and the Heart |
- change in myocardial size and contractility measured by MRI [ Time Frame: before, and 6 months (24 weeks) after, starting disease modifying therapy ] [ Designated as safety issue: No ]
For RA patients, a baseline MRI study will be done before starting disease modifying therapy for RA. Starting therapy is decided by the patient's rheumatologist, so is standard of care. Six months (24 weeks) later a second MRI study will be done to see if treatment changes myocardial size and contractility.
For controls, baseline study only will be done.
Biospecimen Retention: Samples With DNA
serum plasma DNA RNA
| Estimated Enrollment: | 345 |
| Study Start Date: | August 2012 |
| Estimated Study Completion Date: | December 2017 |
| Estimated Primary Completion Date: | December 2017 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
rheumatoid arthritis patients
People who have rheumatoid arthritis
|
|
controls
people who do not have RA or other inflammatory disease
|
Detailed Description:
Aim 1: We want to study people with RA to see if we can detect very early changes in their heart muscle and compare these results to people who do not have RA.
Aim 2: We want to study people with RA, who have at least 4 swollen joints, before and 6 months after starting a disease modifying therapy to see if there are any changes in the heart muscle on treatment.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
people with rheumatoid arthritis and people without rheumatoid arthritis or other inflammatory disease
Inclusion Criteria:
- Written informed consent
- Age >= 18
- RA only: meet ACR criteria for Diagnosis of RA
- Controls only: no evidence of RA or other inflammatory disease
Exclusion Criteria:
- Previous or current heart failure or ischemic cardiovascular disease (eg stroke, myocardial infarction, angina, CABG, stent).
- Atrial fibrillation.
- Known structural or functional cardiac abnormality, including pulmonary htn.
- Glomerular filtration rate < 60 ml/min.
- Pregnancy or breatfeeeding.
- Unable to perform MRI (claustrophobia, unable to fit in magnet,pacemaker,defibrillator or non-MR safe implant).
- Hypersensitivity to gadolinium.
Contacts and Locations| Contact: C. Michael Stein, MD | 615-936-3420 | michael.stein@vanderbilt.edu |
| Contact: Annette M Oeser, MLAS | 615-322-3778 | annette.oeser@vanderbilt.edu |
| United States, Tennessee | |
| Vanderbilt | Recruiting |
| Nashville, Tennessee, United States, 37232 | |
| Principal Investigator: | Charles Michael Stein, MD | Vanderbilt University |
More Information
No publications provided
| Responsible Party: | C. Michael Stein, Dan May Professor of Medicine, Professor of Pharmacology, Assistant Director of the Division of Clinical Pharmacology, Vanderbilt University |
| ClinicalTrials.gov Identifier: | NCT01589770 History of Changes |
| Other Study ID Numbers: | 120314 |
| Study First Received: | April 24, 2012 |
| Last Updated: | September 12, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Vanderbilt University:
|
rheumatoid arthritis inflammation |
Additional relevant MeSH terms:
|
Arthritis Arthritis, Rheumatoid Inflammation Joint Diseases Musculoskeletal Diseases |
Rheumatic Diseases Connective Tissue Diseases Autoimmune Diseases Immune System Diseases Pathologic Processes |
ClinicalTrials.gov processed this record on May 19, 2013